{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-067990","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.918277+00:00","generated_at":"2026-06-11T08:34:48.689331+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bluejay Diagnostics H1 2023 net loss $5.4M; cash down to $5.1M; FDA meeting on IL-6 test","bullets":["Net loss $5.4M ($5.24/sh) vs $4.0M ($2.00/sh) in H1 2022; no revenue reported.","Cash and equivalents fell to $5.1M from $10.1M at Dec 31, 2022; company expects to raise capital near-term.","R&D expense doubled to $3.0M, driven by clinical trial costs for Symphony IL-6 sepsis test.","FDA pre-submission meeting on Aug 11, 2023 confirmed 510(k) pathway; company targets submission in H1 2024.","Sales and marketing expense $302K vs $135K in prior period as company builds commercial infrastructure."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-067990","json":"https://secwatch.observer/filing/0001213900-23-067990.json","markdown":"https://secwatch.observer/filing/0001213900-23-067990.md","text":"https://secwatch.observer/filing/0001213900-23-067990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023067990/0001213900-23-067990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023067990/ea183606-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:34:48.689331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c93b4193b57076c71aba5f960463afe32d5d5d85","claim":"Bluejay Diagnostics, Inc. reported the six months ended June 30, 2023 results: net income $5.4 million, EPS $5.24 per share.","evidence_excerpt":"The net loss for the six months ended June 30, 2023 was $5.4 million, or $5.24 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023067990/0001213900-23-067990-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Net income","value":"$5.4 million"},{"label":"EPS","value":"$5.24 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}